Compare KALA & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALA | RMNI |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 338.2M |
| IPO Year | 2017 | 2015 |
| Metric | KALA | RMNI |
|---|---|---|
| Price | $0.17 | $3.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $31.50 | $5.50 |
| AVG Volume (30 Days) | ★ 7.5M | 253.4K |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.50 | ★ 197.50 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $431,496,000.00 |
| Revenue This Year | N/A | $6.02 |
| Revenue Next Year | N/A | $5.50 |
| P/E Ratio | ★ N/A | $8.41 |
| Revenue Growth | N/A | ★ 5.33 |
| 52 Week Low | $0.16 | $2.87 |
| 52 Week High | $20.58 | $5.38 |
| Indicator | KALA | RMNI |
|---|---|---|
| Relative Strength Index (RSI) | 25.04 | 54.12 |
| Support Level | N/A | $3.05 |
| Resistance Level | $0.72 | $4.08 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 7.66 | 96.97 |
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.